Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 6—June 2004


Antimicrobial Resistance among Campylobacter Strains, United States, 1997–2001

Amita Gupta*Comments to Author , Jennifer M. Nelson*, Timothy J. Barrett*, Robert V. Tauxe*, Shannon P. Rossiter*, Cindy R. Friedman*, Kevin W. Joyce*, Kirk E. Smith†, Timothy F. Jones‡, Marguerit A. Hawkins§, Beletshachew Shiferaw¶, James L. Beebe#, Duc J. Vugia**, Terry Rabatsky-Ehr††, James A. Benson‡‡, Timothy P. Root§§, Frederick J. Angulo*, and for the NARMS Working Group
Author affiliations: *Centers for Disease Control, Atlanta, Georgia, USA; †Minnesota Department of Health, St. Paul, Minnesota, USA; ‡Tennessee Department of Health, Nashville, Tennessee, USA; §Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, USA; ¶Oregon Department of Human Services, Portland, Oregon, USA; #Colorado Department of Public Health & Environment, Denver, Colorado, USA; **California Department of Health Services, Sacramento, California, USA; ††Connecticut Department of Public Health, Hartford, Connecticut, USA; ‡‡Georgia Department of Human Services, Atlanta, Georgia, USA; §§New York State Department of Health, Albany, New York, USA

Main Article

Table 3

Trend analysis of the proportion of fluoroquinolone-resistance among Campylobacter, NARMS, 1997–2001

Y Unadjusted ORa (95% CI) AdjustedORb (95% CI)
1.0 (0.6 to 1.7)
1.3 (0.7 to 2.4)
1.4 (0.9 to 2.3)
2.1 (1.2 to 3.9)
1.1 (0.7 to 1.8)
1.5 (0.8 to 2.8)
2001 1.6 (1.0 to 2.5) 2.5 (1.4 to 4.4)

aOR, odds ratio; CI, confidence interval.
bAdjusted odds ratios were calculated by using logistic regression model, which accounted for site-to-site variation in prevalence.
c1997 was the reference value.

Main Article

1This isolate was reported to be ciprofloxacin resistant in reference